The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NASH. Methods: NASH was induced in Wistar rats using a choline-deficient high-fat diet plus intraperitoneal sodium nitrite injections. First, a dose-finding study was performed with 10 mg/kg and 30 mg/kg of cilofexor, focusing on histological readouts. Liver fibrosis was assessed by Picro-Sirius-Red, desmin staining and hepatic hydroxyproline content. Gene expression was determined by RT-PCR. In a subsequent hemodynamic study, rats received 30 mg/kg cilofexor with or without propranolol (25 mg/kg). Portal pressure, systemic hemodynamics and splanchnic blood flow were measured. Results: Cilofexor dose-dependently induced FXR target genes shp, cyp7a1 and fgf15 in hepatic and ileal tissues, paralleled by a dose-dependent reduction in liver fibrosis area (Picro-Sirius-Red) of −41% (10 mg/kg) and −69% (30 mg/kg), respectively. The 30 mg/kg cilofexor dose significantly reduced hepatic hydroxyproline content (−41%), expression of col1a1 (−37%) and pdgfr-β (−36%), as well as desmin area (−42%) in NASH rats. Importantly, cilofexor decreased portal pressure (11.9 ± 2.1 vs. 8.9 ± 2.2 mmHg; p = 0.020) without affecting splanchnic blood-flow or systemic hemodynamics. The addition of propranolol to cilofexor additionally reduced splanchnic inflow (−28%) but also mean arterial pressure (−25%) and heart rate (−37%). Conclusion: The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While rodent models have demonstrated a striking reduction in portal hypertension with FXR agonism,130 its effect on HSC activation may possibly be more preventive than therapeutic in vitro.131”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078 · cited 1×
“The only oral medication to decrease portal pressure and incidence of PH-associated complications are non-selective beta-blocker (NSBB), like propranolol or carvedilol [4].”
BackgroundAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · cited 1×
“The prognosis of NASH patients is significantly affected by the degree of hepatic fibrosis and portal hypertension (PH) [3].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“Desmin was used as an HSC activation marker since its hepatic expression is highly specific for HSCs in rodents [18].”
MethodYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277 · cited 1×
“In preclinical and clinical studies, FXR agonists improved the histological features of NASH and reduced liver fibrosis [9,10].”
BackgroundGuha, I. N., Parkes, J., Roderick, P., Chattopadhyay, D., Cross, R., Harris, S., Kaye, P., Burt, A. D., Ryder, S. D., Aithal, G. P., et al. (2008) · Hepatology · doi:10.1002/hep.21984 · Cited by 745 · cited 4×
“Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome, which affects about one-quarter of the Western population [1].”
BackgroundInfluentialBile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634 · cited 1×
“The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism, inflammation and the sinusoidal vascular tone [7,8].”
BackgroundSelf-citationThe epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 606
Mandorfer, M., Bota, S., Schwabl, P., Bucsics, T., Pfisterer, N., Kruzik, M., Hagmann, M., Blacky, A., Ferlitsch, A., Sieghart, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.005 · Cited by 378
Self-citationPatel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270 · cited 1×
“The CDHFD/NaNO2 model was well-suited to assess these effects since it presents a portal hypertensive phenotype with hyperdynamic circulation, whereas pure diet-induced NASH models often only show signs of steatohepatitis and mild fibrosis but lack PH [24].”
Background
Research works printed but not linked: 4
- Kirby, 2016, Evaluation of the Safety and Pharmacokinetic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers, Hepatology, 64, 574A
- Liu, 2018, FXR Agonist GS-9674 Decreases Hepatic Fibrosis in a Mouse Model of Advanced Fibrosis Due to Nash, Hepatology, 68, 1009A
- Younossi, 2019, Patient-reported outcomes (PROs) in patients with primary sclerosing cholangitis (PSC) during treatment with cilofexor (GS-9674), Hepatology, 70, 805A
- Kowdley, 2019, The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): A phase 2, randomized, placebo-controlled trial, Hepatology, 70, 31A
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“For example, the FXR agonists obeticholic acid and cilofexor can reduce liver fibrosis in mouse models 238,239 , and a phase III trial of obeticholic acid including 1,968 patients with NASH demonstrated an improvement in liver fibrosis 240 .”
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Bile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 231
Self-citationFXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 184
Self-citation
Metadata
- Authors
- Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., Watkins, W. J., Trauner, M., Breckenridge, D. G., Kremoser, C., & Reiberger, T.
- Affiliations
- Medical University of Vienna (AT)
- Phenex Pharmaceuticals (Germany) (DE)
- Gilead Sciences (United States) (US)
- Synovo (Germany) (DE)
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
- Austrian Academy of Sciences (AT)
- Corresponding author
- Reiberger, Thomas
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2021-01-09
- Volume
- 9
- Issue
- 1
- Pages
- 60
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC7827357
- OpenAlex
- W3120249619
- Cited by
- 70
- References
- 29
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 15 · 2023: 16 · 2022: 11 · 2021: 11
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- This research was funded by Gilead Sciences and Phenex Pharmaceuticals (GS9674)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- farnesoid X receptor agonist, nonalcoholic steatohepatitis, portal hypertension, liver fibrosis, propranolol, choline-deficient high-fat diet, sodium nitrite, hepatic hydroxyproline, splanchnic circulation, hepatic hemodynamics, FGFR1, CYP7A1, COL1A1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. https://app.cochat.ai/papers/10.3390/biomedicines9010060
- The paper
- Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., Watkins, W. J., Trauner, M., Breckenridge, D. G., Kremoser, C., & Reiberger, T. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. https://doi.org/10.3390/biomedicines9010060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.